BioNTech
Biotech

BioNTech’s mRNA cancer vaccine fails phase 3 test

With immature OS data offering a path to redemption, the German biotech is continuing to track patients in the metastatic head and neck cancer study.
Nick Paul Taylor Oct 13, 2026 8:48am
two arrows pointing different directions

Paragon Labs imports Apogee leadership after AbbVie buyout

Oct 13, 2026 8:44am
iRegene Therapeuticss NouvSight001 Cleared for Clinical Trials in the US and China for Retinitis Pigmentosa

iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

Brought to you by iRegene Therapeutics
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: Soufflé & more

Oct 13, 2026 8:00am
Roche

Roche inks $1.16B Rona deal to enter emerging obesity race

Oct 13, 2026 7:45am
Pfizer

Pfizer pens $500M Enodia pact to join Lilly in emerging field

Oct 13, 2026 7:00am
More News

Nurix drops BTK degrader, as Roche-partnered asset enters ph. 3

Oct 13, 2026 3:16am

Roche sets sights on July FDA ruling with updated eye drug data

Oct 12, 2026 9:42am

Tortugas’ schizophrenia drug proves worth in ph. 2 Hansoh trial

Oct 12, 2026 9:23am

BMS doubles up with pivotal wins in lung disease, solid tumor

Oct 12, 2026 8:05am